Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial
- 31 March 2023
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 25 (4) , 250-259
Abstract
Aim: To assess long-term efficacy and safety of open-source automated insulin delivery (AID) in children and adults (7–70 years) with type 1 diabetes. Methods: Both arms of a 24-week randomized controlled trial comparing open-source AID (OpenAPS algorithm within a modified version of AndroidAPS, preproduction DANA-i™ insulin pump, Dexcom G6 continuous glucose monitor) with sensor-augmented pump therapy (SAPT), entered a 24-week continuation phase where the SAPT arm (termed SAPT-AID) crossed over to join the open-source AID arm (termed AID-AID). Most participants (69/94) used a preproduction YpsoPump ® insulin pump during the continuation phase. Analyses incorporated all 52 weeks of data, and combined between-group and within-subject differences to calculate an overall “treatment effect” of AID versus SAPT. Results: Mean time in range (TIR; 3.9–10 mmol/L [70–180 mg/dL]) was 12.2% higher with AID than SAPT (95% confidence interval [CI] 10.4 to 14.1; P < 0.001). TIR was 56.9% (95% CI 54.2 to 59.6) with SAPT and 69.1% (95% CI 67.1 to 71.1) with AID. The treatment effect did not differ by age ( P = 0.39) or insulin pump type ( P = 0.37). HbA1c was 5.1 mmol/mol lower [0.5%] with AID (95% CI −6.6 to −3.6; P < 0.001). There were no episodes of diabetic ketoacidosis or severe hypoglycemia with either treatment over the 48 weeks. Six participants (all in SAPT-AID) withdrew: three with hardware issues, two preferred SAPT, and one with infusion-site skin irritation. Conclusion: Further evaluation of the community derived automated insulin delivery (CREATE) trial to 48 weeks confirms that open-source AID is efficacious and safe with different insulin pumps, and demonstrates sustained glycemic improvements without additional safety concerns.Keywords
This publication has 20 references indexed in Scilit:
- A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery SystemDiabetes Technology & Therapeutics, 2021
- Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic reviewActa Diabetologica, 2020
- A Randomized Trial of Closed-Loop Control in Children with Type 1 DiabetesNew England Journal of Medicine, 2020
- CREATE (Community deRivEd AutomaTEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetesJournal of Diabetes & Metabolic Disorders, 2020
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018Diabetes Technology & Therapeutics, 2019
- International Consensus on Use of Continuous Glucose MonitoringDiabetes Care, 2017
- Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2017
- Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin DeliveryDiabetes Technology & Therapeutics, 2017
- glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed ModelingThe R Journal, 2017